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Abstract 
Background: This article summarizes a EUFOREA symposium, presented during the European Rhinology Research 
Forum in Brussels (9–10 November 2017; https ://www.rhino logyr esear ch.eu/) which focused on novel pathways and 
therapeutic approaches in allergic rhinitis (AR).
Main body: AR remains under-diagnosed, under-estimated and under-treated. A key component in understanding 
the AR landscape has been the realization of a significant mismatch between how physicians instruct AR patients to 
manage their disease and what AR patients actually do in real life. Data from the Allergy Diary (developed by MACVIA 
ARIA) showed that AR patients take their medication prn, rapidly switch treatments, often experience poor control, 
use multiple therapies and stop treatment when symptoms are controlled. Better control of AR may be achievable 
by using an AR treatment which has a rapid onset of action and which effectively targets breakthrough symptoms. 
Indeed, AR patients report complete symptom relief, lack of breakthrough symptoms, rapid onset of action, safety 
and use on an ‘as needed’ basis as key targets for new nasal sprays. MP-AzeFlu comprises intranasal azelastine and 
fluticasone propionate (FP) in a novel formulation delivered in a single device. It is the first AR treatment to break the 
5 min onset of action threshold and provides clinically relevant symptom relief in 15 min, much faster than that noted 
for FP + oral loratadine. MP-AzeFlu also significantly reduces nasal hyperresponsiveness (NHR) which may be respon-
sible for the breakthrough symptoms frequently reported by AR patients. Mechanisms underlying MP-AzeFlu’s effect 
include inhibition of mast cell degranulation, stabilization of the mucosal barrier, synergistic inhibition of inflamma-
tory cell recruitment and a unique desensitization of sensory neurons expressing the transient receptor potential A1 
and V1 channels.
Conclusion: With the most rapid onset of action and onset of clinically-relevant effect of any AR medication currently 
available, and proven efficacy in the treatment of NHR, MP-AzeFlu is an AR treatment which provides what patients 
want, and fits how patients manage their AR in real life.
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Background
The European forum for research and education in 
allergy and airways diseases (EUFOREA; http://www.
eufor ea.eu/) is an international non-profit organisation, 
forming an alliance of all stakeholders, from national and 
international organizations, institutions, and agencies 
working towards a common aim. The aim of EUFOREA 
is to reduce preventable and avoidable burden of mor-
bidity and disability due to chronic airway diseases using 
personalized medicine, so that affected populations reach 
the highest attainable standards of health and productiv-
ity at every age, with these diseases no longer represent-
ing a barrier to patients’ well-being or socioeconomic 
development [1].
Allergic rhinitis (AR) represents the most common 
chronic airway disease in the world, affecting some 500 
million individuals [2]. When symptomatic, AR sufferers 
experience a significant impairment of their quality of life 
[3], with negative effects apparent in all areas of daily liv-
ing [4], and importantly impaired school performance [5] 
and work productivity [6, 7]. AR is a significant risk fac-
tor for the development of asthma [8], commonly occurs 
with asthma and affects asthma control to the same 
degree as smoking [2, 9–11]. The socioeconomic burden 
of AR in Europe is high, due mostly to its impact on work 
productivity [12]. Treatment of AR has been well iden-
tified [13] and algorithms are available [14]. Precision 
medicine is an important approach [15].
The second European Rhinology Research Forum held 
in Brussels (9–10 November 2017; https ://www.rhino 
logyr esear ch.eu/), under the auspices of EUFOREA [16, 
17] and the European Rhinologic Society, sought to 
explore research needs and priorities in upper airway 
diseases. A EUFOREA symposium presented during 
this meeting focused on novel pathways and therapeutic 
approaches in AR. The aim of this article is to summarize 
this symposium, and to discuss how the novel data pre-
sented may impact the management of AR.
What patients with AR want
The aim of AR management is to gain control of the dis-
ease. As for asthma, the control concept is important 
for the rhinitis management landscape [18, 19]. Unfor-
tunately, many patients with AR continue to live with 
uncontrolled disease [20]. In order to understand how 
AR control may be achieved in real-life, it is necessary to 
understand the complexity of the AR management land-
scape, and to know what AR patients really expect from 
their treatment.
Complexity of the AR landscape manifests in many 
ways. Firstly, a disparity exists in perspectives between 
physicians and AR patients, to the effect that AR is 
under-diagnosed, under-estimated and under-treated; 
the majority of physicians do not use adequate AR treat-
ment [21]. Secondly, AR patient behaviour, as it pertains 
to their AR management, can be disorganized and incon-
sistent [22–24]. Up to two-thirds of AR patients simply 
forget to take their medication [24]. Thirdly, there is a 
reticence to seek professional medical advice, and a ten-
dency to do so only when symptoms become ‘intolerable’ 
[22] or if symptoms persist after trying several over the 
counter (OTC) options [23]. An internet and telephone 
survey conducted with 2966 randomly selected adults 
with allergies showed that 52.6% of respondents had not 
seen a medical professional in the past year for their rhi-
nitis symptoms, with some 30.2% preferring non-pre-
scription medication because it did not involve a doctor 
visit [22]. Fourthly, AR patients glean a lot of informa-
tion about their disease from the internet, and there is 
a high degree of self-management, a consequence of the 
large choice of OTC AR medications available [25–28]. 
It is therefore, crucial that AR care pathways should con-
sider pharmacists [29]. The vast majority of AR patients 
use 2 or more AR medications in an effort to achieve 
faster and more effective relief from their nasal and ocu-
lar symptoms [30] (a practice which is not endorsed by 
the evidence) [31–33], with many patients calling for 
more efficacious OTC AR medications to better man-
age their AR symptoms [23]. Finally, most patients suf-
fer from several episodes of short-term AR symptoms 
[30], and so rarely take their medication continuously 
for 14 days, as envisaged in the vast majority of seasonal 
AR randomized controlled trials (RCTs). Indeed, there is 
little evidence supporting the daily use of rhinitis treat-
ment. For example, a recent study of pollen-AR in chil-
dren found that on-demand fluticasone propionate (FP) 
treatment was at least as effective as a regular treatment 
at a lower dose [34].
To gain a better understanding of what patients want 
from their AR treatment, we should simply ask them. A 
survey conducted in Belgium showed that patients have 
high expectations from their AR treatment and have 
preferences in terms of AR medication delivery and 
approach [35]. 40% of these patients expected their AR 
to be cured by pharmacological intervention, with 30% 
preferring intranasal sprays (vs 24% for oral therapy), and 
31% of respondents preferring a combination treatment 
with a step down approach. When asked, AR patients 
listed good symptom relief, lack of breakthrough symp-
toms, rapid onset of action, safety and use on an ‘as 
needed’ basis as key targets for new nasal sprays [23]. A 
different type of patient survey, called a discrete choice 
experiment quantified what patients want from their AR 
treatment, using a willingness to pay metric, and con-
firmed the results of the AR patient surveys [23, 35, 36]. 
The findings showed that patients want more complete 
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symptom relief from their AR treatment and are will-
ing to pay £43.81 (approx. €55) to achieve that (vs mild 
relief ). Rapidity of response was also very important to 
AR patients, both in terms of time to maximum response 
and time to first response (i.e. onset). Patients were will-
ing to pay £0.98 (approx. €1.10) for each hour faster to 
onset and £0.62 (approx. €0.70) for each day faster to 
maximum complete relief from AR symptoms. These sur-
veys highlight the importance of involving patients in AR 
management and tailoring the AR treatment to the indi-
vidual. By listening to AR patients we can empower them 
to establish their own treatment goals, manage treatment 
expectations, and incorporate treatment preferences into 
their AR treatment regimen. And this has benefits for the 
physician too; up to 96% of physicians consider that tak-
ing AR patients’ opinions into account increases thera-
peutic adherence [37]. Patient participation in the design 
of the treatment strategy is one of the 4 key pillars of pre-
cision medicine and believed to be a key success factor of 
treatment [17].
MACVIA-ARIA (Contre les Maladies Chroniques pour 
un Vieillissment Actif-Allergic Rhinitis and its Impact 
on Asthma) have recommended a patient-centered, 
mobile-health and clinical decision support system 
(CDSS) approach to achieve AR control in real life, link-
ing all stakeholders in AR management (i.e. patients, 
healthcare providers (HCPs), regulators and guideline 
producers/implementers) [38]. This has been done by 
establishing a common language of AR control, a sim-
ple visual analogue scale (VAS) [18, 19, 39], and incor-
porating this VAS into free apps for patients [7, 40–42] 
and HCPs, as well as into an AR CDSS [18]. A VAS score 
cut-off of 5/10  cm is used to assess control and guide 
treatment decisions [18]. Allergy Diary is the app for 
patients. It is part of the MASK initiative (Mobile Air-
ways Sentinel networK), and is included in the B3 action 
plan of the European Innovation Partnership on Active 
and Health Aging [43]. Data obtained from the Allergy 
Diary have enabled us for the first time to see how 
patients really treat their AR in real life and to recognize 
how this vastly differs from the RCT environment. The 
Allergy Diary data showed that In real-life patients (1) 
are poorly compliant with their AR treatment; (2) rapidly 
switch from one AR treatment to another if the desired 
response is not achieved; (3) often use multiple AR 
therapies; (4) fail to achieve sustained AR control on an 
Fig. 1 Allergic rhinitis (AR) control according to treatment in a single Allergy Diary user. VAS: visual analogue scale; AH: anti-histamine; INS: intranasal 
corticosteroid; MP-AzeFlu (MP-azelastine/fluticasone propionate); AR: allergic rhinitis. Reprinted with permission from MACVIA-ARIA
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intranasal corticosteroid (INS) monotherapy or anti-his-
tamine + INS therapy; (5) achieve good control on more 
effective therapies, like MP-AzeFlu  (Dymista®, Mylan 
Inc, USA); but (5) often switch back to less effective ther-
apies when AR is well-controlled. Figure 1 shows Allergy 
Diary data from one typical AR user,inputted between 
Aug and Dec 2015. As can be seen, treatment is neither 
consistent nor consecutive. This user started with a mul-
tiple treatment regimen (INS + anti-histamine), switch-
ing to MP-AzeFlu (or MP-AzeFlu + anti-histmanine) to 
achieve MACVIA-ARIA defined disease control (i.e. VAS 
score < 5/10  cm). AR control was lost upon swiching to 
INS monotherapy, and regained once again on MP-Aze-
Flu (Fig. 1).
Better AR control may be achieved by listening to 
patients, taking account of how they actually manage 
their AR and providing what they want. Based on the 
evidence presented here, patients want an AR therapy, 
which provides complete and long-lasting symptom relief 
(i.e. no breakthrouh symptoms) and which has a rapid 
onset of action.
Speed of onset of rhinitis treatment
MP-AzeFlu, is a relatively new addition to the AR treat-
ment armamentarium, comprising intranasal azelas-
tine (AZE) and FP in a novel formulation delivered in a 
single device [44]. Its onset of action has recently been 
investigated in an allergen exposure chamber and com-
pared with an AR treatment regimen frequently used 
by AR patients in real life (i.e. anti-histamine + INS), in 
a single-centre, double-blind, double-dummy 3-period 
cross-over RCT [45]. AR symptoms were induced in 
asymptomatic patients (n = 82) in response to ragweed 
pollen challenge in the Ontario environmental expo-
sure chamber. Patients then received a single dose of 
MP-AzeFlu (137/50  μg, 1 spray/nostril); intranasal FP 
(50 μg, 1 spray/nostril) plus oral loratadine (LOR; 10 mg) 
or placebo, and were monitored for 4 h. Symptoms were 
assessed at 5, 10, 15, 30, 60, 90, 120, 150, 180, 210 and 
240 min after dosing. The primary outcome was onset of 
action measured by total nasal symptom score (TNSS). 
The TNSS comprises individual scores for nasal conges-
tion, itching, rhinorrhoea and sneezing, with each of 
these scored from 0 (none) to 3 (severe), giving a maxi-
mum score of 12. Clinical relevance was assessed both 
from the individual and population perspective, using 
Kaplan–meier curves for time to response and mini-
mally important clinical difference (MICD), respectively. 
A clinically relevant response was defined as at least 50% 
change from baseline in TNSS. MICD for TNSS was cal-
culated using a sample size adjusted pooled estimate of 
baseline standard deviations. A difference of 0.47 points 
was defined as a small effect and 1.17 points defined as a 
medium effect [45].
Fig. 2 Effect of MP-AzeFlu, FP + LOR and placebo on nasal symptoms. Data are presented as mean change from baseline in total nasal symptom 
score (TNSS) assessed over a period of 4 h following exposure to ragweed pollen in an allergen exposure chamber. Arrow: onset of action; dotted 
arrow: onset to clinically relevant effect compared to placebo (i.e. 1.17 change in TNSS). MP-AzeFlu (MP-azelastine/fluticasone propionate;  Dymista®; 
1 spray/nostril; 138 μg/50 μg); FP (fluticasone propionate;  Flonase®; 1 spray/nostril; 50 μg) + LOR (Loratadine;  Claritin®; 10 mg). LS: least squares; SE: 
standard error. *p ≤ 0.005 vs placebo;  †p = 0.038 vs placebo; ‡p ≤ 0.003 vs FP + LOR. Modified from Bousquet et al. 2017 [45]
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As can be seen from Fig. 2, the onset of action for MP-
AzeFlu was 5  min compared to 150  min for FP + oral 
LOR, a difference of almost 2.5  h [45]. MP-AzeFlu also 
provided significantly (p = 0.005) greater nasal symptom 
relief than FP + LOR, which did not differ from placebo 
during the 4  h study period (p = 0.182). Furthermore, 
MP-AzeFlu achieved the 1.17 medium MICD in rTNSS 
at 15  min, compared to both placebo and to FP + LOR. 
By contrast, patients treated with FP + LOR experi-
enced this difference vs placebo at 210  min, more than 
3  h later. When assessing clinical relevance in terms of 
50% reduction from baseline in TNSS, 71.3% of patients 
treated with MP-AzeFlu achieved this clinically rele-
vant response, and did so significantly faster than those 
treated with FP + LOR (p < 0.001) or placebo (p = 0.002), 
approximately 2.5 h faster [45]. MP-AzeFlu’s rapid onset 
of action and rapid clinically relevant effect should 
improve AR control, with this profile fitting well with prn 
use of AR medications and rapid treatment switching 
observed in real life.
Targeting nasal hyper‑reactivity
As many as 36.5% of patients currently on an AR treat-
ment continue to experience poorly controlled AR (i.e. 
VAS score ≥ 5), with this number remaining essentially 
the same irrespective of the type of pharmacological 
treatment used, be it INS (38.5%), oral anti-histamine 
(34.9%) or multiple therapies (35.9%) [20]. This situation 
is familiar to HCPs, who consider that 58% of their AR 
patients have either uncontrolled or poorly controlled 
disease [39]. Lack of AR control is influenced by 4 fac-
tors, namely (1) diagnosis-related (e.g. incorrect diagno-
sis, presence of co-morbidity); (2) treatment-related (e.g. 
insufficient efficacy or lack of targeted symptom relief ); 
(3) patient-related (e.g. poor adherence); and (iv) disease-
related (e.g. treatment resistant phenotypes) [19]. Using 
an AR treatment with a rapid onset of action and rapid 
clinically relevant effect is one way to improve AR con-
trol, presumably by addressing patient-related factors; 
improving adherence to therapy, or perhaps being more 
forgiving of poor adherence. Another way to achieve bet-
ter AR control is to address disease-related factors by 
targeting an alternative disease pathway. Nasal hyper-
reactivity (NHR) is an important clinical feature of AR, 
which is present in up to two-thirds of AR patients [46], 
and may be responsible for breakthrough symptoms fre-
quently reported by AR patients and dissatisfaction with 
treatment. NHR is defined as an increased sensitivity of 
the nasal mucosa to environmental, non-specific stim-
uli (e.g. temperature/humidity changes, smoke, strong 
odours, exercise and emotional stress), leading to nasal 
symptoms [47, 48]. The effect of MP-AzeFlu on cold dry 
air (CDA)-induced-NHR was assessed in a 4-week dou-
ble-blind, placebo-controlled trial in 28 AR patients with 
a house dust mite sensitivity [49].
Patients with moderate/severe persistent AR 
and NHR (i.e. reduced peak nasal inspiratory flow 
(PNIF) > 20% upon CDA provocation) were rand-
omized 2:1 to receive either MP-AzeFlu (1 spray/nos-
tril bd) or placebo. The effect of MP-AzeFlu on NHR 
was assessed by PNIF decrease in response to CDA, as 
well as on the severity of nasal symptoms, measured 
at baseline and after 7 and 28  days of treatment [49]. 
Nasal symptom severity was assessed in two ways, by 
total of 5 symptom scores (T5SS; comprising scores 
for congestion, nasal itching, rhinorrhoea, sneez-
ing and ocular itching—max score = 15) and by VAS 
(0–10 cm). AR control was assessed using the AR con-
trol test. To investigate the mechanism(s) behind any 
observed reduction in NHR, the effect of MP-AzeFlu 
on substance P and β-hexosaminidase concentrations 
in human nasal secretions was assessed. MP-AzeFlu’s 
effect on mucosal barrier integrity, mast cell degranu-
lation and airway inflammation in a mouse model of 
house dust mite-induced NHR, as well as its effect on 
murine sensory neurons from trigeminal ganglia was 
also investigated [49].
The results showed that MP-AzeFlu significantly 
(p < 0.0001) reduced NHR (Fig.  3a), with a correlat-
ing and significant reduction in nasal symptom sever-
ity observed (Fig.  3b, c) [49]. Nasal symptoms were 
reduced following 28  day’s treatment with MP-AzeFlu 
by approximately 80% when assessed by T5SS and 
by 90% when assessed by VAS. Patients treated with 
MP-AzeFlu for 28  days also experienced significantly 
(p = 0.035) better AR control compared to placebo. An 
investigation of the underlying pathophysiology of this 
NHR reduction revealed that MP-AzeFlu significantly 
reduced Substance P (p = 0.026) and β-hexosaminidase 
concentrations (p = 0.036) in nasal secretions, both 
at Day 7 and Day 28, which was not found in the pla-
cebo group [49]. In  vitro, AZE + FP inhibited human 
mast cell degranulation (better than FP and to the 
same extent as AZE) and decreased murine epithelial 
permeability (better than AZE and to the same extent 
as FP). MP-AzeFlu also totally abrogated eosinophils 
(and neutrophils) in bronchoalveolar lavage fluid in the 
same murine model of HDM-induced allergic airway 
inflammation, compared to both AZE and FP, dem-
onstrating a synergistic effect on airway inflammation 
[49]. Furthermore, only AZE + FP (and not AZE or FP 
alone) evoked a rapid intracellular  Ca2+ increase, with 
repeated applications of AZE + FP resulting in desen-
sitization of sensory neurons expressing the transient 
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receptor potential (TRP) A1 and V1 channels [49]. 
Activation of these neuronal channels is responsible for 
the development of idiopathic rhinitis and non-allergic 
hyperreactivity [50, 51]. MP-AzeFlu’s specific targeting 
of NHR represents a novel pathway in the pathophysi-
ology of AR, helping to explain the clinical superiority 
and over-additive effects of MP-AzeFlu seen in clinical 
practice [52, 53], and providing patients with the com-
plete symptom relief and lack of breakthrough symp-
toms that they want.
Discussion
Despite abundant treatment options, AR remains uncon-
trolled for many patients [39, 54, 55] who are unsurpris-
ingly dissatisfied with their treatment [56]. Dissatisfaction 
leads to decreased compliance and increased reliance 
on multiple therapies, including OTC medications [24]. 
Indeed, 60% of AR patients are “very interested” in find-
ing a new medication, and 25% are “constantly” trying 
different medications to find one that “works” [24]. AR 
patients also frequently feel that their HCP does not 
take their disease seriously and does not understand 
their personal treatment needs [24]. This lack of effective 
communication between patients and HCPs most likely 
contributes to the burden of disease, poor AR control, 
non-compliance and unhappiness for many patients.
AR control may be significantly improved by improving 
communication with patients and by prescribing a treat-
ment which takes account of their preferences, expec-
tations and treatment behaviour in real life. MACVIA 
ARIA has recognized the importance of these issues, by 
developing apps for AR patients and their physicians to 
improve communication [42], and by highlighting the 
importance in the guidelines of patient preference when 
considering choice of treatment [33]. According to the 
discrete choice experiment data, AR patients have a 
strong preference for a treatment which has a rapid onset 
of action and provides clinically-relevant symptom relief. 
MP-AzeFlu is the first AR treatment to break the 5 min 
onset of action threshold [45], much faster than that 
observed for FP + oral LOR (150  min), or other classes 
of AR therapy or multiple therapy, measured in the same 
chamber [57–61]. An AR treatment with a rapid onset of 
action should encourage AR patients to take it. However, 
in order for patients to continue taking their AR medi-
cation it must also provide rapid clinically-relevant relief. 
Measured in a RCT setting MP-AzeFlu provided com-
plete symptom relief days faster than an INS [52]. Now, 
using the more appropriate chamber study design, the 
onset of clinically relevant symptom relief for MP-AzeFlu 
is just 15 min, compared to 210 min for FP + LOR [45]. 
Future AR guidelines should be modified to take account 
of these new data.
AR control may also be improved in real-life by recog-
nizing that many AR patients also experience NHR [46], 
and by providing a treatment which targets not only the 
usual complement of nasal and ocular symptoms associ-
ated with AR, but NHR too. The study by Krohn and col-
leagues [49] is the first to show an effect of MP-AzeFlu 
on NHR, and to elucidate the cellular pathways under-
lying this effect. Some of MP-AzeFlu’s novel properties 
include its ability to reduce mast cell mediators and neu-
romodulators, and to restore or maintain the mucosal 
barrier, thus preventing ingress of allergens to the sub-
mucosa. Furthermore, AZE and FP worked synergisti-
cally together to reduce airway inflammation in vitro and 
interacted in a unique way to desensitize sensory neurons 
expressing TRPA1 and TRPV1 [49]. Others have found 
that treatment with topical mometasone furoate objec-
tively reduced nasal congestion and NHR to histamine in 
children and adolescents with PAR [62].
Conclusion
Taken together these data should change the way that AR 
is managed in real-life by encouraging frank and open 
communication with patients, as well as prescription of 
medication which takes patient preferences, disease phe-
notype and treatment behaviour into account. It’s time to 
take a more pragmatic approach to AR management in 
order to provide a personalized medicine, centred around 
the patient [63]; to recognize that in real-life patients do 
not behave as they do in RCTs. A pragmatic approach 
involves fitting the AR treatment to the patient, rather 
than the patient to the treatment. With the most rapid 
onset of action and onset of clinically-relevant effect of 
any AR medication currently available, as well as proven 
efficacy in the treatment of NHR, MP-AzeFlu is an AR 
treatment which is tailored to the patient.
(See figure on next page.)
Fig. 3 Effect of MP-AzeFlu on nasal-hyperreactivity induced by cold dry air provocation. Nasal hyper-reactivity assessed by a PNIF (peak nasal 
inspiratory flow), b T5SS (total of 5 symptom scores) and c VAS (visual analogue scale) at day 7 (V1) and day 28 (V2) post-treatment. MP-AzeFlu 
(MP-azelastine/fluticasone propionate;  Dymista®; 1 spray/nostril bd; 137 μg/50 μg). CDA: cold dry air. *p < 0.001 vs Day 1; ** p < 0.0001 vs Day 1; 
† p=0.03 vs placebo; ‡ p=0.003 vs placebo. Modifed from Krohn et al. 2017 [49]
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